NCT06589440 2026-01-15
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Stingray Therapeutics
Phase 2 Recruiting
Clinical Trials
1 trialsINDUSTRY × Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) × 1 year × Clear all